Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer

Дата публикации: 23-10-2026 00:00:00

This randomized, multicenter, phase 3 trial compares progression-free survival with trastuzumab rezetecan vs physician’s choice of chemotherapy in patients with ERBB2-low metastatic breast cancer.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer Research Summary	0	12.56	23-10-2026
2	Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer	0	9.5	23-10-2026
3	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
4	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
5	Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor	0	25.38	12-10-2026
6	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026
7	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023
8	Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer	0	7	22-08-2024
9	‘Why do I have this cancer?’ At CNIO, breast cancer research gets personal	0	10.34	21-10-2026
10	New therapeutic strategy could open the door to preventing brain metastasis	0	7.7	29-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 15.98. Источник: www.jamanetwork.com.